Meeting
2015 ASCO Annual Meeting
Bendamustine and rituximab and lenalidomide (BRR) in the treatment of relapsed and refractory low grade non-Hodgkin lymphoma (NHL): Final results of phase 1 study NCCTG N1088/ALLIANCE.
Authors
Grzegorz S. Nowakowski
Mayo Clinic, Rochester, MN
Grzegorz S. Nowakowski , Betsy LaPlant , William R Macon , Morie A. Gertz , Thomas Matthew Habermann , David James Inwards , Ivana N. M. Micallef , Donald B. Wender , John Leonard , Thomas E. Witzig
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01429025
Citation
J Clin Oncol 33, 2015 (suppl; abstr 8540)
DOI
10.1200/jco.2015.33.15_suppl.8540
Abstract #
8540
Poster Bd #
357
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Phase 1b/3 study of avelumab-based combination regimens in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Robert W. Chen
Poster
2015 ASCO Annual Meeting
A phase I study combining bendamustine with rituximab, etoposide and carboplatin (TREC) in patients with aggressive relapsed or refractory lymphoma.
First Author: L. Elizabeth Budde
Poster
2013 ASCO Annual Meeting
Results of a phase I/II study (NCT01365559) of carfilzomib (CFZ) replacing bortezomib (BTZ) in BTZ-containing regimens for BTZ-treated patients (pts) with relapsed and refractory multiple myeloma (MM).
First Author: James R. Berenson
Poster
2011 ASCO Annual Meeting
Bendamustine and lenalidomide in relapsed/refractory lymphoid malignancies.
First Author: B. D. Cheson